HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data

Executive Summary

FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement
Advertisement

Related Content

FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
GSK Coreg Post-MI Survival Backed By Beta Blocker Experience – FDA Cmte.
GSK Coreg Post-MI Survival Backed By Beta Blocker Experience – FDA Cmte.
Merck Cozaar Approval Nod For Nephropathy Gets Boost From Avapro Data
Advertisement
UsernamePublicRestriction

Register

PS040514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel